Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Collaborates With Major Private Hospital In Northeast China

This article was originally published in PharmAsia News

Executive Summary

Siemens China has signed a strategic agreement to establish a partnership with Wekang Medicinal Group, the first private Class III hospital in Northeast China. Under the agreement, Siemens will provide Wekang with a full set of radiological and in vitro diagnostic equipment worth about RMB 70 million ($10.2 million), complemented by leasing services; introduce advanced global experience of hospital management procedures and help medical care staff further their studies in overseas hospitals; and assist Wekang to set up a tumor treatment center in the future. The fully equipped Wekang hospital will go into operation in late 2009. Siemens said it is exploring new collaborative models with local corporations by providing leading healthcare products and solutions. (Click here for more - Chinese Language)

You may also be interested in...

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Health And Wellness Trademark Review 26 May, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts